Fig. 6.
MG132 and Nutlin-3 mitigated the sevoflurane-induced cognitive impairment in young mice. (A) In the mice pretreated with dimethyl sulfoxide (DMSO), two-way analysis of variance (ANOVA) with repeated-measurement analysis showed a significant interaction of treatment (control vs. sevoflurane) and time (days 31 to 37) on escape latency of MWM (F = 2.202, P = 0.048). Mice with the sevoflurane anesthesia plus DMSO had longer escape latency compared with that in the mice with control plus DMSO at days 35, 36, and 37. (B) The sevoflurane anesthesia decreased the platform-crossing times compared with the control condition. (C) Two-way ANOVA with repeated-measurement analysis showed no significant interaction of treatment (control vs. sevoflurane) and time (days 31 to 37) on escape latency of MWM in the mice pretreated with MG132 (F = 0.795, P = 0.576). (D) The sevoflurane anesthesia did not decrease the platform-crossing times as compared to the control conditions in the mice pretreated with MG132. (E) In the mice treated with Nutlin-3, two-way ANOVA with repeated-measurement analysis showed no significant interaction of treatment (control vs. sevoflurane) and time (days 31 to 37) on escape latency of the Morris water maze in the mice pretreated with Nutlin-3 (F = 1.238, P = 0.292). (F) The sevoflurane anesthesia did not decrease the platform-crossing times as compared to the control conditions in the mice pretreated with Nutlin-3. N = 10 to 11 in each group.